To block, or not to block in advanced cirrhosis and ascites: That is the question

Gut

Volumn 64, Issue 7, 2015, Pages 1015-1017

  Krag, Aleksander ^a   Madsen, Bjørn Stæhr ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; NON SELECTIVE BETA BLOCKER; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ASCITES; BACTERIAL PERITONITIS; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; ESOPHAGUS VARICES BLEEDING; HEPATORENAL SYNDROME; HUMAN; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; META ANALYSIS (TOPIC); MODEL FOR END STAGE LIVER DISEASE SCORE; NOTE; PRIORITY JOURNAL; RISK ASSESSMENT; SURGICAL MORTALITY; SURVIVAL RATE; TREATMENT OUTCOME; END STAGE LIVER DISEASE; FEMALE; MALE; MORTALITY;

ASCITES; END STAGE LIVER DISEASE; FEMALE; HUMANS; MALE;

EID: 84935008451     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-308424     Document Type: Note

References (15)

1. Hamer J, Grandjean T, Melendez L., et al. Effect of Propranolol (Inderal) in Angina Pectoris: Preliminary Report. Br Med J 1964; 2:720-3.
2. Lebrec D, Nouel O, Corbic M., et al. Propranolol-a medical treatment for portal hypertension? Lancet 1980; 2:180-2.
3. Serste T, Melot C, Francoz C., et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology 2010; 52: 1017-22.
4. Mandorfer M, Bota S, Schwabl P., et al. Nonselective beta blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology 2014; 146: 1680-90.e1.
5. Thiele M, Krag A, Rohde U., et al. Meta-analysis: banding ligation and medical interventions for the prevention of rebleeding from oesophageal varices. Aliment Pharmacol Ther 2012; 35:1155-65.
6. Gluud LL, Krag A. Banding ligation versus beta-blockers for primary prevention in oesophageal varices in adults. Cochrane Database Syst Rev 2012; 8:CD004544.
7. Leithead JA, Rajoriya N, Tehami N., et al. Non-selective beta-blockers are associated with improved survival in patients with ascites listed for liver transplantation. Gut 2015; 64:1111-19.
8. Wiest R, Krag A, Gerbes A. Spontaneous bacterial peritonitis: recent guidelines and beyond. Gut 2012; 61:297-310.
9. Kim SB, Kim WR, Larson J.J., et al. The effect of long-term use of non-selective beta-blockers on the development of acute kidney injury in patients with liver cirrhosis. Hepatology 2014; 60:227A.
10. Krag A, Wiest R, Albillos A., et al. The window hypothesis: haemodynamic and non-haemodynamic effects of beta-blockers improve survival of patients with cirrhosis during a window in the disease. Gut 2012; 61:967-9.
11. Laine L, Cook D. Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding: a meta-analysis. Ann Intern Med 1995; 123:280-7.
12. Bernard B, Lebrec D, Mathurin P., et al. Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis 4. Hepatology 1997; 25: 63-70.
13. Li L, Yu C, Li Y. Endoscopic band ligation versus pharmacological therapy for variceal bleeding in cirrhosis: a meta-analysis. Can J Gastroenterol 2011; 25:147-55.
14. Robins A, Bowden A, Watson W., et al. Beta-blockers in cirrhosis patients with refractory ascites. Hepatology 2014; 59:2054-5.
15. Kimer N, Feineis M, Moller S., et al. Beta-blockers in cirrhosis and refractory ascites: a retrospective cohort study and review of the literature. Scand J Gastroenterol Published Online First: 12 Aug 2014.